Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), on Friday reported two-year follow-up data from the Phase III STARGLO study, showing a 40% improvement in overall survival for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) treated with Columvi (glofitamab-gxbm) plus GemOx chemotherapy.

Median overall survival was not reached in the Columvi arm, compared to 13.5 months with Rituxan plus GemOx.

The study included patients who had received at least one prior therapy and were not eligible for autologous stem cell transplant. Among patients who achieved a complete response, 89% were alive and 82% maintained remission one year post-treatment.

Columvi also showed a 59% reduction in the risk of disease progression or death and more than double the complete remission rate versus the control arm. The combination's safety profile was consistent with known individual therapies, with low-grade cytokine release syndrome among the most common adverse events.

Columvi in combination with GemOx is now approved in over 30 countries for second-line treatment of R/R DLBCL in non-transplant candidates. It has been designated a category 1 preferred option in the National Comprehensive Cancer Network Clinical Practice Guidelines.

These results support the potential of Columvi as a fixed-duration, off-the-shelf treatment option in a setting where timely, effective therapy is critical. Data will be presented at the American Society of Clinical Oncology annual meeting from 30 May to 3 June 2025.